Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $36
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $32 to $36.
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $32 to $36.